The Motley Fool’s “King Kong for Weight Loss” pitch name-checks a drug, but what it is really selling is a handful of companies at wildly different stages of maturity. Understanding the obesity drug space means understanding those companies individually, because a trillion-dollar pharma giant, a revenue-growing biotech, and a pre-revenue microcap have almost nothing in common beyond the shared label. Here is the company map behind the theme.
The Established Leaders
Two companies own most of the commercial obesity drug market today. Novo Nordisk makes semaglutide, the molecule behind Ozempic and Wegovy, and it has spent years building the manufacturing and marketing muscle to defend its lead. Eli Lilly makes tirzepatide, behind Mounjaro and Zepbound, and is advancing retatrutide, the triple receptor agonist that anchors the Fool’s pitch.
What separates these two is diversification. Both are large, profitable pharmaceutical companies with diabetes, obesity, and other franchises, which means their obesity drugs are one engine inside a much bigger machine. That diversification makes them the lowest-risk way to own the theme, but it also means the next drug will not move their share prices the way it would move a small biotech.
The Differentiated Challengers
The next tier is made up of companies with real technology but less scale. Ascendis Pharma is the most established of these, with product revenue up 105% year over year, and its angle is delivery: a version of semaglutide dosed once a month instead of once a week. Viking Therapeutics is further back, pre-revenue, but it is one of the more credible oral candidates with VK2735, plus an amylin program that could add a second mechanism.
The distinction between these two is instructive. Ascendis already sells products, so you can judge it on revenue growth and execution. Viking sells nothing yet, so you are buying data risk. Both are “challengers,” but they are not the same kind of investment at all.
The Non-Traditional Players
Then there are the companies that stretch the definition of “obesity drug company.” Hims & Hers Health does not develop drugs at all. It runs a telehealth platform that sells compounded semaglutide directly to consumers, which is legal only while the branded drug is in shortage. When that shortage resolves, the business has to pivot. It is a real, fast-growing revenue stream, but it is a distribution play with a regulatory clock, not a drug company.
Scholar Rock is stranger still in this context. Its lead asset, apitegromab, is a muscle-preservation drug for spinal muscular atrophy, not a weight-loss medicine. It appears in the Fool’s basket on the theory that preserving muscle during weight loss is the next frontier, which is a legitimate idea but a thin thread connecting a neuromuscular drug to an obesity portfolio.
The Small and the Speculative
At the far end sits Veru, a roughly $39 million microcap with an early-stage oral GLP-1 candidate. A company that small is a fundamentally different instrument from everything above it. Its stock can double or halve on a single piece of news, and its financing runway is a risk factor the larger names simply do not have.
This is the key lesson of the whole basket: the promo groups six companies as if they were one trade, but they are six different trades with six different risk profiles. Our King Kong weight loss teardown walks through exactly how different those six picks are, and our GLP-1 stocks explainer covers the category from the stock side.
What to Actually Look For
When evaluating an obesity drug company, three questions do most of the work. Does it have revenue today, or is it a pure data bet? Does it have a differentiated mechanism or delivery advantage, or is it another me-too entry in a crowded race? And how dependent is its business on a temporary regulatory window? The answers sort the entire space into quality, speculative, and transient buckets, and that sorting matters far more than any single headline number.
What Separates the Winners
If the obesity market plays out the way the bulls expect, the winners will be separated by a handful of unglamorous factors. Manufacturing scale comes first, because a drug only matters if it can be produced at the volume the market demands. Distribution and payer relationships come second, because getting a medicine onto formularies and into pharmacies is a contest in its own right. Tolerability comes third, because real-world adherence depends on how a patient feels day to day, not on the headline efficacy number. And cost comes fourth, because drugs taken indefinitely by huge populations will face pricing pressure. None of these factors shows up in a single trial readout, but together they decide which of the many obesity drug companies actually converts a good molecule into a durable franchise.
Ready to see the research? Click here to access The Motley Fool’s report.
NewsletterVetter is an independent publication. We receive compensation from some of the services we review through affiliate links. Nothing on this site is investment advice. Always do your own research.